Access TOC
Download Data
December 2024
The epigenetics market size was valued at US$ 14.70 billion in 2023 and is predicted to reach US$ 61.15 billion by the end of 2033, representing an impressive CAGR of 15.32% from 2024 to 2033. The decline in sequencing costs, the rise in next-generation sequencing applications worldwide, and product advancements are anticipated to propel the epigenetics market's expansion.
Unlock Infinite Advantages: Subscribe to Annual Membership
The epigenetics market revolves around study, research, medicine, healthcare, pharmacy, and other disciplines associated with epigenetics. The study of epigenetics focuses on how cells regulate gene expression without altering the DNA sequence. Throughout the history of biology, one of the areas that has grown the fastest is epigenetics. In the animal and plant worlds, phenotypic variation among species is significantly influenced by epigenetics.
Despite this uncertainty, the field of epigenetics is vibrant, pushing the boundaries of technology while also questioning and updating long-held biological beliefs. The traditional genetic works are now viewed from new angles thanks to epigenetics, and when taken together, they aid in our understanding of the functions and interactions of DNA, RNA, proteins, and environment in heredity and the etiology of illness. In addition to helping to better understand the complexity of genetic control, cellular differentiation, embryology, aging, and illness, the epigenetics market is expected to make it possible to methodically investigate new therapeutic paths that may eventually lead to customized medicine.
| Company Name | Epigenica |
| Headquarters | Stockholm, Sweden |
| Breakthrough | In June 2024, Epigenica, a start-up that is leading the way in the application of multiplex, high-throughput tools in epigenomic research, launched EpiFinder Genome, an extensive genome-wide profiling tool, and unveiled its EpiFinderTM Platform, which includes a patented high-throughput, multiplexing, quantitative ChIP-seq (hmqChIP-seq) technology. The company's main offering, EpiFinder Genome, targets up to eight markers simultaneously in up to 24 samples or independent repetitions. It is the first commercial kit of its sort. It produces quantifiable data that may be utilized to learn more about precision medicine, biomedical research, diagnostics, and medication development. |
| Company Name | PacBio |
| Headquarters | California, U.S. |
| Breakthrough | In May 2024, in an effort to help families dealing with uncommon disorders, Ambry Genetics and PacBio announced a partnership to sequence up to 7,000 human genomes. The researchers want to find novel, uncommon variants and comprehend the impact of epigenomics on illness manifestation by utilizing an extremely precise 5-base, long-read sequencing technique. The scientists intend to find novel Mendelian gene variations and more accurately classify previously found variants of uncertain importance by developing new processing methods for this genomic and epigenomic data. |
The epigenetics market is growing due to the continuous focus on research and development for developing therapies, drugs, and personalized medicines. Key players, along with government organizations, are making efforts to use epigenetics to understand the role of environmental factors in genetic modifications. Neurological problems and cancer are two examples of the many illnesses and diseases in which epigenetics is crucial. Researchers have discovered that variations in the epigenetic states of sick and healthy cells can act as useful disease indicators. Drug development has been greatly affected by epigenetics, with a number of medications and treatments that target epigenetic changes already on the market. Drug development and epigenetic research have a bright future ahead of them, with a particular emphasis on individualized care and customized therapies.
For instance,
A considerable amount of public concern has been raised over the past few decades by a few high-profile cases of genetic discrimination. There are disagreements about whether it is morally or legally acceptable to use a person's genetic information to deny some person access to a range of social benefits. When we talk about genetic discrimination, we generally mean unfair acts by insurance companies or employers that could be inclined to demand that people take a genetic test or reveal the findings. Nations all across the world have enacted a variety of public policies to solve this issue.
A person's health and sickness can be better understood by studying their genome and the information that goes along with it. For accurate illness management and prediction, genomic techniques, including the detection of DNA sequence variants, transcriptomics, proteomics, and metabolomics, are helpful. These methods serve as helpful links between customized medicine and epigenetics. Patient-specific epigenetic and medication management data can be leveraged to personalize medical care. Scholars are now exploring the potential of employing epigenetic techniques to create tailored treatment strategies for certain ailments, including schizophrenia, psychological disorders, and heart problems. There is a lot of room for expansion in the epigenetics market due to the increasing demand for medications and individualized care.
For instance,
By product type, the reagents segment dominated the epigenetics market in 2023. Using a variety of reagents is essential in laboratory settings to carry out experiments, carry out chemical reactions, and get correct findings. Reagents are essential for the binding of antibodies, the facilitation of analytical procedures, and the synthesis of targeted molecules. There are several grades of reagents available, each having specialized uses and properties based on the application. It is essential for scientists and researchers to comprehend the many kinds of laboratory reagents and how to utilize them in order to carry out studies efficiently and provide reliable findings. Activities such as DNA methylation, RNA transcription, histone medication, DNA purification, PCR, assay, etc., are conducted in epigenetics for which reagents are needed.
By technology, the DNA methylation segment dominated the epigenetics market with the largest share. Histone modification and non-coding RNA-mediated control of gene expression are two additional common epigenetic processes that impact gene expression. DNA methylation is one of these mechanisms, suppressing gene expression in different ways and influencing the activity of these other two mechanisms. Of the three known methods of epigenetic control of gene expression, DNA methylation is the one that has been researched the most. Up to now, a substantial body of research has been conducted to demonstrate the pivotal role this mechanism plays in the emergence of several autoimmune and neurodegenerative disorders in people.
For instance,
By technology, the histone acetylation segment is expected to grow at the fastest rate during the forecast period. Primarily, histone acetylation is an epigenetic modification that affects gene expression by determining whether transcription factors can access or not access certain genes. In order to activate the transcription of genes, histone acetylation is necessary. Since it was the first alteration of histones to be shown to affect transcriptional control, acetylation is one of the most researched histone modifications. Epigenetics can be used to study the regulation of many other cellular processes, such as cellular differentiation, nuclear import, neuronal repression, DNA replication and repair, and cell cycle regulation, along with the involvement of histone acetylation in cell proliferation, apoptosis, and regulation of many other functions.
By application, the oncology segment dominated the epigenetics market in 2023. Since the response of cancer cells to therapeutic treatments is governed by their epigenome, progress in understanding the landscape of cancer epigenetics is imperative as precision medicine becomes more practically applied. Novel insights into several cancer treatment models that identify aberrant epigenetic modifications are offered by advanced epigenetic therapy. In the field of malignant tumor therapy and individualized precision diagnostics, this is a significant advancement. The market for epigenetics is becoming increasingly important for oncology since cancer is becoming more common, particularly as a result of changing environmental factors.
For instance,
By application, the non-oncology segment is estimated to grow at the fastest CAGR during the forecast period. The focus of research over the past 20 years has been on developing epigenetic therapies to address oncological pathways and identifying epigenetic therapeutic targets in cancer. However, as evidence of the relevance of epigenetic pathways to numerous non-oncological diseases grows, scientists are becoming more interested in this area. Epigenetics can help lower the burden of diabetes and cardiovascular illnesses, two non-oncology diseases that are on the rise.
For instance,
By end-use, the clinical research segment is expected to witness the fastest growth during the forecast period. The epigenetics market is at a budding stage and is growing at a high pace. Key players and government organizations are making efforts to incorporate epigenetics in the development of drugs or medicines for the treatment of various diseases. Clinical research is continuously occurring to study how factors beyond the genetic code impact functioning and how they can be used to understand further the functions that occur in the body, which may or may not lead to serious conditions.
By region, North America held the largest epigenetics market share in 2023. North America significantly contributes to the market's growth due to its technological advancements, government support, and the presence of key market players. The U.S. and Canada significantly contribute to the growth. Significant public funding, as well as private contributions, support the U.S. epigenetics market. The need for sophisticated diagnostic technologies and tailored therapy is driven by the increasing frequency of chronic illnesses, particularly cancer, in the nation.
For instance,
Although the Canadian epigenetics industry is still smaller than the American one, it is expanding quickly as a result of increased government funding and research efforts. Significant funding for genetic and epigenetic research is provided by the Canadian Institutes of Health Research (CIHR) and other organizations. Significant breakthroughs in the subject have been made possible by the active participation of Canadian scholars in international partnerships.
By region, Asia Pacific is estimated to grow with the fastest CAGR during the forecast period. The region is growing continuously with emerging technology and contributions by various countries, including China, India, Japan, and South Korea. Among these countries, China and India play significant roles in the growth of the epigenetics market in the Asia-Pacific region.
Asian nations continue to embrace Chinese Medicine (CM), which has been a part of human health care for several millennia. In the wake of constantly advancing molecular technology, CM research on epigenetics has clearly improved lately. Epigenetics' holistic, dynamic, individual, and environment-interacting qualities align well with the fundamental principles of Traditional Chinese Medicine (TCM), which is practiced extensively in China and many other Asian and Western nations. The process of DNA methylation modification is regulated by TCM, which has been shown to have a significant anti-tumor impact in several investigations on the anti-tumor effect of TCM.
| Perception | % Responding |
| One of today's most exciting biological target areas, somewhat comparable to kinase situation, just time is needed to develop | 51% |
| It will remain challenging until the biology and screening tools catch up with the hype | 41% |
| The lack of follow-up biology will create a significant obstacle for the foreseeable future | 4% |
| It will never be like the kinase situation as the assays and methodologies are too diverse | 4% |
| No point in screening or profiling targets that have unknown disease relevance | 0% |
Most people (51%) think epigenetic screening is a very promising area of research, similar to kinase research, but needs more time to develop. A smaller group (41%) is more cautious, thinking it's overhyped and needs better understanding of the biology and tools. Only a few (8%) have a negative view of epigenetic screening.
By Product
By Technology
By Application
By End-use
By Region
December 2024
December 2024
December 2024
December 2024
Annual Access, Limitless Research! Unlock all market research reports with our annual subscription. Stay on top of market trends and crucial insights year-round!
2500+
Client Queries in 20235000+
Insights Published60+
Consulting Projects Per Year40+
Analysts